Payer coverage for wound care is shaped by trials that excluded your typical patient, by quality measures built for other specialties, and by policy decisions made on thin real-world evidence. A 60-year-old with a six-month-old wound and six comorbidities rarely resembles the population in a pivotal trial, yet that trial often defines what a Medicare Administrative Contractor (MAC) will pay for. The seven strategies below show clinicians and administrators how to document, measure, and present outcomes so that coverage decisions reflect the patients you actually treat.
1. Make documentation meet policy criteria
Coverage policies are written as checklists, and reviewers audit against them. A Local Coverage Determination (LCD) is the policy a MAC issues to define when a service is reasonable and necessary in its jurisdiction. For skin substitutes and cellular and/or tissue-based products (CTPs), the audited elements usually include wound duration, dated area measurements, treatments tried and for how long, and the comorbidities that affect healing. Hyperbaric oxygen therapy (HBOT) for diabetic wounds is governed nationally by National Coverage Determination 20.29, which requires a Wagner grade III or higher wound and no measurable signs of healing after at least 30 days of standard wound therapy, and reviewers audit it against the same kinds of elements. Skin substitute policy is also in flux: the multi-MAC skin substitute LCDs scheduled to take effect January 1, 2026 were withdrawn by CMS days before their effective date, so existing MAC policies still apply, while the CY 2026 payment changes for skin substitutes went forward. If the chart does not show those elements, the reviewer cannot credit them, regardless of what happened in the room. For a deeper look at how these policies work, see understanding Local Coverage Determinations.
Consider an illustration. A diabetic foot ulcer chart records dated length-by-width measurements at each visit, the offloading device and patient adherence, each debridement, and infection assessment and management. It survives review. A second chart describes the same care in narrative paragraphs with no measurements. It does not, because the reviewer has nothing to map to the criteria.
To put this into practice:
- Build wound care EHR templates with required fields for wound measurements, standard-of-care steps, and comorbidities, so a note cannot be signed without them.
- Train staff on why each field exists, tying it to the specific LCD language.
- Audit a sample of charts each month against the current LCD, and update templates when policy changes. Policies and effective dates move, so confirm the current text on your MAC’s website.
The most common failure is copy-forward text. Notes that omit measurements, or repeat identical wording across visits, signal to a reviewer that the visit was not individually assessed. Disable or restrict copy-forward for assessment fields.
Measure the share of audited charts that meet every policy criterion, and track the denial rate for documentation reasons. If the first rises and the second falls, the templates are working. Better structure also helps structured wound care data reach analysis later, since the same fields feed outcome reporting.
2. Capture failed standard of care with measured area change
Most advanced-therapy policies require proof that conservative care was delivered for a defined period and that the wound did not respond. The proof is a measured area change over a dated window. Without a baseline, there is nothing to compare against, and a payer can reasonably conclude the wound was never given a fair trial of standard care. The diabetic foot ulcer healing rate you document is exactly the kind of benchmark reviewers look for.
Take a venous leg ulcer as an illustration. Compression adherence is logged weekly, and the area is measured at baseline and again at the end of the policy window. The reduction falls short of the percentage the policy specifies, so the record shows both that care was delivered and that it failed. A patient-specific barrier, such as a documented inability to tolerate high-compression wraps, is recorded alongside it.
Steps that make this routine:
- Record baseline area and date at the first visit, using the same measurement method every time.
- Schedule the reassessment at the end of the policy window when the baseline is recorded, not when someone remembers.
- Calculate percent area change in the chart and document any barriers to adherence.
- Only then request the advanced therapy.
The classic mistake is starting a CTP or other advanced therapy before the standard-of-care window is documented, or discovering at the reassessment that no baseline exists. Neither can be fixed retroactively. A hard stop in the ordering workflow, requiring baseline and reassessment fields before an advanced-therapy order, prevents both.
Measure the percentage of advanced-therapy starts that have a documented baseline and a window reassessment. Anything under 100 percent is a list of cases to review, and each one is a potential denial.
3. Use risk-adjusted measures
Risk adjustment is a statistical method that accounts for differences in patient characteristics, such as age, diabetes, vascular disease, wound size, and wound duration, so that outcomes can be compared fairly. Raw healing percentages punish centers that take on the hardest patients and reward those that screen them out. A payer medical director who suspects this will discount unadjusted numbers, and rightly so.
Imagine two centers with identical raw healing rates. One treats a younger, healthier population. The other treats older patients with more comorbidities, larger wounds, and longer wound duration. After adjustment, the second center performs better than expected, and the first performs about as expected. The raw number hid the difference that matters to anyone judging quality.
To implement this:
- Collect risk variables at intake, including comorbidities, wound characteristics, and duration, rather than reconstructing them later.
- Report through a Qualified Clinical Data Registry (QCDR) that offers risk-adjusted wound measures. A QCDR is a CMS-approved entity that collects clinical data and submits quality measures for MIPS, including measures developed for specialties poorly served by the standard menu.
- Review your results against registry benchmarks quarterly and investigate gaps.
The mistake is presenting raw healing percentages to payers without case-mix context. It invites the response that your patients must be easier than average, or it sets an expectation you cannot meet with a sicker population. Always pair a rate with a description of who was treated.
Track risk-adjusted healing relative to the registry benchmark, and watch the trend over time rather than any single quarter. Small centers will see noisy quarterly numbers, so report confidence intervals where possible.
4. Turn MIPS QCDR reporting into evidence
Many practices treat the Merit-based Incentive Payment System (MIPS) as a penalty-avoidance exercise: submit something, avoid a negative adjustment, move on. That wastes the data. If you capture structured clinical data once and report it through a QCDR, the same record supports MIPS credit and serves as outcome evidence for payer conversations. It removes the double data entry that clinicians resent most. A MIPS registry comparison can help you choose a reporting partner that supports this approach.
For example, a wound center might report specialty measures through the US Wound Registry (USWR) and then reuse the same data set to describe its healing outcomes, by wound type and comorbidity burden, in a discussion with a regional payer.
A workable sequence:
- Select measures for clinical relevance to your patient population, not only for ease of scoring. Hospital-based programs can start with MIPS measures for hospital outpatient wound centers.
- Map the registry’s data elements to fields in your EHR so they populate from routine charting.
- Run test submissions and fix gaps before the reporting period closes.
- Verify current CMS deadlines and performance-year requirements on cms.gov, since thresholds and dates change.
Two mistakes recur. Practices pick the measures they will score highest on, which yields credit but no insight. Others keep a registry spreadsheet on the side of the EHR, so every patient is entered twice and completeness collapses.
Measure your MIPS performance on each reported measure, the data completeness rate, and the staff minutes spent per patient entry. If minutes per entry are not falling, the mapping is incomplete.
5. Use registry data to fill the trial gap
Randomized trials are built to isolate a treatment effect, so they exclude patients with poor perfusion, uncontrolled diabetes, multiple comorbidities, or very long-standing wounds. Coverage policies then rely on those trials and are silent, or restrictive, about the people left out. A real-world registry fills that gap because it records everyone treated, including the complex patients clinicians see every day. For more on this approach, read about strengthening diabetic foot ulcer clinical trials with real-world registry data.
Registry data have already been used this way in a payment decision. When the physician work value for hyperbaric chamber supervision was re-evaluated, the USWR’s Hyperbaric Oxygen Therapy Registry supplied national data showing that HBOT patients typically carry multiple serious comorbidities and medications. The rate was still reduced, but the registry data helped establish a fair analysis of the physician work involved rather than leaving the decision to assumptions.
To build a useful evidence set:
- Define the cohort precisely: wound type, treatment, time window, and exclusion rules.
- Pull outcomes stratified by comorbidity, age, and wound characteristics, so reviewers can see results in the patients trials left out.
- Pair those results with published trial citations, positioning the registry as complementary evidence, not a replacement.
The central pitfall is overclaiming causation. Observational data cannot prove that a therapy caused healing, because treatment selection and unmeasured confounders shape who received it. State what the data show, describe the limitations, and use risk adjustment or matched comparisons where the design allows. Payers and CMS reviewers read these limits closely, and an overclaim costs credibility on everything else you say.
Measure cohort size, how well each major comorbidity group is represented, and the number of policy submissions that cite registry data. A cohort too small to stratify will not persuade anyone, so know that before you submit.
6. Engage when policies are proposed
Coverage rules are easiest to influence before they are final. MACs post proposed LCDs with an open comment period, and CMS publishes proposed payment rules with their own deadlines. Comments that arrive on time and carry data are part of the record the decision makers must consider. Evidence windows open outside formal rulemaking, too; in July 2026, CMS reopened its call for clinical evidence on skin substitutes. Silence leaves the field to those with a different interest.
As an illustration, a society coalition might submit comments during an LCD open comment window that include aggregated registry outcomes for the patients the proposal would affect, alongside clinical context from its members. That is far more useful to a medical director than a letter stating that the policy will harm patients.
To make this routine:
- Track MAC and CMS notices, including proposed LCDs and rulemaking, with a named person responsible for monitoring.
- When a proposal affects your services, calendar the deadline and prepare data cuts early, such as outcomes by wound type and comorbidity.
- Join society and coalition efforts, since coordinated comments from organizations such as wound care and podiatry societies carry weight and spread the workload.
- Cite specific sections of the proposal and propose concrete alternative language.
The two mistakes are timing and substance: commenting after the deadline, and relying on anecdotes alone. A single dramatic patient story is memorable, but it does not substitute for a stratified analysis. Showing the scale of the problem with figures on the chronic wound economic burden can strengthen the case.
Measure the number of comments submitted before the deadline, and record what changed in the final policy. Attribution is imperfect, but a log of submissions and outcomes shows over time where your input has been effective.
7. Build outcome-backed prior auth and appeal packets
Denials are where coverage policy meets the individual patient. A generic appeal letter makes the reviewer do the work of finding evidence in the chart. A packet that maps patient data directly to each policy criterion makes approval the easy decision. As health care attorney Knicole Emanuel has noted, providers tend to win appeals when the full clinical story is finally read.
Suppose a negative-pressure wound therapy (NPWT) claim is denied. The appeal includes the wound’s measured trend over time, the comorbidities that complicate healing, the prior treatments and their dates, and a table that walks through the payer’s criteria one by one, citing the chart entry that satisfies each. The reviewer can verify every point in minutes.
To standardize this:
- Create a template with sections for the criteria, supporting chart excerpts, and a clinical summary.
- Assign a coordinator who owns packet assembly, so clinicians review and sign rather than draft.
- Log every denial by payer and stated reason.
- Review the log monthly to find patterns, and feed them back into documentation templates from the first strategy.
The frequent mistake is sending a generic letter that never addresses the cited denial reason. If the denial says the standard-of-care window was not documented, the appeal must show the window, not restate that the therapy is beneficial. Read the denial first and answer it directly.
Measure the appeal overturn rate and the time to decision, broken out by payer and denial reason. Those figures show which payers respond to evidence and which denial categories point to a documentation fix upstream.
Where to start, and how the pieces fit together
Begin with documentation and failed-standard-of-care capture, because every other strategy depends on them. Appeals, registry analyses, and policy comments are only as strong as the chart behind them. Once those habits are stable, add QCDR reporting with risk-adjusted measures, so the same data earns MIPS credit and produces outcomes that stand up to scrutiny. Move to policy engagement and registry-based evidence submissions once your data is credible enough to withstand a skeptical reviewer.
If you want to see how a registry can turn routine charting into MIPS credit and defensible outcomes, learn more about our services.
Recent Comments